Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($6.00) per share for the quarter.
Enveric Biosciences Stock Up 0.6 %
NASDAQ:ENVB opened at $1.74 on Friday. The company has a market capitalization of $1.18 million, a PE ratio of -0.05 and a beta of 0.47. Enveric Biosciences has a 52-week low of $1.13 and a 52-week high of $17.85. The stock’s 50 day moving average price is $2.65 and its 200 day moving average price is $5.04.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Enveric Biosciences in a research report on Thursday, March 6th.
About Enveric Biosciences
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
See Also
- Five stocks we like better than Enveric Biosciences
- How to Start Investing in Real Estate
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What is an Earnings Surprise?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Are Dividend Contenders? Investing in Dividend Contenders
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
